Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide PK in Renal Impairment
NCT04933747Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of iberdomide in systemic lupus erythematosus (SLE) and multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Iberdomide Pharmacokinetics - Area Under the Curve from Time Zero to Last Quantifiable Concentration up to 72 hours, Metabolite M12 Pharmacokinetics - Area Under the Curve from Time Zero to Last Quantifiable Concentration up to 72 hours and 14 more. Started Aug 2021; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04933747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933747.